Recent studies are revealing that GLP-1 agonist drugs, commonly known as weight-loss jabs, may have a significant impact beyond managing obesity, potentially treating addiction. This emerging evidence challenges long-held stigmas and calls for a more pragmatic approach to healthcare.
Evidence of Broader Benefits
A study using data from US veterans undergoing diabetes treatment indicated that patients on GLP-1 drugs were less likely to develop addictions to various substances. Those already using drugs appeared about half as likely to suffer overdose or drug-related death when taking these jabs. This suggests that these medicines, which work on satiation and reward centres in the brain, could address cravings not just for food but for drugs as well.
Stigma and Moralising in Healthcare
Despite their potential, GLP-1 drugs face considerable stigma, particularly in the context of obesity. Many argue that weight loss should be achieved through willpower and lifestyle changes, not medication. For instance, Germany covers these drugs for diabetes but not general obesity, with officials citing individual responsibility. This moralising contrasts sharply with how addiction is increasingly viewed as an illness requiring medical intervention.
Prof Chris Whitty, England's chief medical officer, has cautioned against relying solely on prescriptions, emphasising the need for policies promoting healthier food. While valid, this perspective must balance with the reality that one in eight Americans and about one in 20 people in the UK have already used GLP-1 drugs, highlighting their widespread adoption.
Learning from Addiction Treatment
The history of addiction treatment offers a valuable lesson. When methadone and suboxone were introduced, resistance based on abstinence-only beliefs was common, but pragmatism eventually prevailed. Similarly, if GLP-1 drugs prove effective for addiction, it should prompt reflection on why obesity, with its severe health impacts, remains stigmatised.
David A Kessler, former head of the US Food and Drug Administration, notes in his book that the effectiveness of anti-obesity drugs underscores obesity as a biological issue, not a lack of discipline. This aligns with the understanding gained about addiction, suggesting it's time to extend this knowledge to obesity treatment.
Pragmatic Steps Forward
While GLP-1 drugs have downsides, such as high costs and side-effects like an increased risk of vision loss, their potential benefits cannot be ignored. As research progresses, these medicines may be recommended or prescribed off-label for addiction, urging a shift from moral judgement to evidence-based care. By embracing this approach, healthcare systems can better address complex conditions without stigma.
